clinical trial · NCT06198764
A Clinical Trial for the Treatment of Carbapenem Resistant Gram-negative Bacterial Infection With Colistimethate Sodium for Injection
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.·phase3·unknown·n = 80
Mental Health IssueColistimethate sodium for injectionMeropenem for InjectionColy Mycin M Injectable Product
brief summary
A clinical study to evaluate Colistimethate Sodium for Injection combination with Meropenem versus Coly-Mycin® M Parenteral combined with Meropenem in the treatment of Carbapenem resistant gram-negative bacteria infection. A total of 80 patients will be enrolled in the study.
started
Jul 6, 2023
primary completion
Mar 1, 2026
completion
Mar 1, 2026
last updated
Jan 10, 2024
official title
A Multicenter, Randomized, Open, Parallel Controlled Clinical Study to Evaluate the Efficacy and Safety of Colistimethate Sodium for Injection in the Treatment of Carbapenem Resistant Gram-negative Infections in Chinese Adults.
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol